几年后。荷兰儿童婴幼儿肺炎球菌疫苗接种成本效益的最新情况。
A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.
作者信息
Vemer Pepijn, Postma Maarten J
机构信息
a PharmacoEpidemiology & PharmacoEconomics (PE2); University of Groningen; Groningen, The Netherlands.
出版信息
Hum Vaccin Immunother. 2014;10(7):1841-9. doi: 10.4161/hv.29008.
This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICER) of PCV13 over PCV10.Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of €11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICER of PCV13 compared with PCV10 was below €30 000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below €2.63 per dose.
本研究旨在计算在荷兰使用13价肺炎球菌结合疫苗（PCV13）与目前使用的10价肺炎球菌结合疫苗（PCV10）相比，婴儿接种肺炎球菌疫苗的成本效益。我们采用了之前发表的模型，并使用了最新的流行病学和疗效数据估计值。在12种情景中，我们探讨了不同假设对PCV13相对于PCV10的增量成本效益比（ICER）的影响。仅考虑对侵袭性肺炎球菌疾病的直接影响时，发现每剂价格相差11欧元的情况下，PCV13不具有成本效益。如果也考虑群体保护、替代和非侵袭性疾病，在12种情景中的11种情景下，PCV13与PCV10相比的ICER低于每获得一个质量调整生命年（QALY）30000欧元。在主要情景中，当每剂价格相差低于2.63欧元时，PCV13被认为占主导地位。
Zotero 插件